Risk of Incident Inflammatory Bowel Disease in New Users of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Dependent Glucose Co-Transporter 2 Inhibitors in the FDA Sentinel System Read more about Risk of Incident Inflammatory Bowel Disease in New Users of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Dependent Glucose Co-Transporter 2 Inhibitors in the FDA Sentinel System
Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Obesity: A Descriptive Analysis Read more about Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Obesity: A Descriptive Analysis
Utilization of Ibrexafungerp in Pregnant Women: An Updated Descriptive Analysis Read more about Utilization of Ibrexafungerp in Pregnant Women: An Updated Descriptive Analysis
Intentional Self-Harm Algorithm Defined in "Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes: An Inverse Probability of Treatment Weighting Analysis" Read more about Intentional Self-Harm Algorithm Defined in "Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes: An Inverse Probability of Treatment Weighting Analysis"
Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes: An Inverse Probability of Treatment Weighting Analysis Read more about Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes: An Inverse Probability of Treatment Weighting Analysis
Duration of Follow Up for New Molecular Entities Approved in 2021: First Descriptive Analysis Read more about Duration of Follow Up for New Molecular Entities Approved in 2021: First Descriptive Analysis
Duration of Follow Up for New Molecular Entities Approved in 2020: First Descriptive Analysis Read more about Duration of Follow Up for New Molecular Entities Approved in 2020: First Descriptive Analysis
Duration of Follow Up for New Molecular Entities Approved in 2019: Second Descriptive Analysis Read more about Duration of Follow Up for New Molecular Entities Approved in 2019: Second Descriptive Analysis
Duration of Follow Up for New Molecular Entities Approved in 2018: Second Descriptive Analysis Read more about Duration of Follow Up for New Molecular Entities Approved in 2018: Second Descriptive Analysis
Prevalence of Selected Conditions Among Individuals with Childbearing Potential: A Descriptive Analysis Read more about Prevalence of Selected Conditions Among Individuals with Childbearing Potential: A Descriptive Analysis